BOC Sciences provides comprehensive late-stage formulation development services that bridge the gap between early-phase candidate characterization and commercial-ready drug products. With deep expertise in formulation optimization, process scale-up, stability assessment, container closure development, and technology transfer, we help pharmaceutical and biotechnology teams refine lead formulations into robust, scalable, and analytically well-characterized dosage forms. Every project is supported by integrated analytical capabilities, systematic risk evaluation, and application-oriented data packages designed to advance programs toward manufacturing readiness.
Late-stage formulation development is the systematic process of transforming a lead formulation into a stable, manufacturable, and quality-controlled drug product suitable for pilot-scale production and eventual commercial manufacturing. It encompasses formulation optimization, process parameter definition, scale-up studies, stability evaluation, specification establishment, packaging selection, and technology transfer. Unlike early-stage development, which focuses on feasibility and proof of concept, late-stage work demands rigorous control over critical quality attributes, process reproducibility, and product performance under real-world manufacturing and storage conditions.
We refine lead formulations by systematically evaluating and adjusting composition, processing parameters, and performance attributes to achieve a robust, scalable drug product. Our approach uses Design of Experiments (DoE) to understand factor interactions and define an operating space that accommodates normal manufacturing variability.
We develop scalable manufacturing processes and systematically transfer them from laboratory to pilot scale, identifying and mitigating scale-dependent risks before they impact product quality or timeline.
We establish scientifically justified specifications and robust analytical methods that reflect formulation composition, manufacturing process understanding, and stability behavior.
We design and execute stability programs that characterize degradation pathways, establish shelf-life expectations, and confirm that the optimized formulation maintains quality throughout its intended storage period.
We evaluate and select packaging systems that protect the formulation from environmental stressors, maintain sterility where required, and are compatible with the intended route of administration and manufacturing process.
We facilitate the structured transfer of formulation and process knowledge from development to manufacturing, ensuring that receiving sites can reproducibly manufacture the drug product with consistent quality.
BOC Sciences helps development teams move from early formulation leads to optimized, scalable, and analytically well-characterized drug products with the data packages needed for partner handover.
BOC Sciences provides formulation development, process optimization, stability testing, and technology transfer support across a broad range of dosage forms and product types. Key project categories include:
| Formulation Type | Service Scope & Key Activities |
| Oral Solid Formulations | Optimization of immediate-release and modified-release tablets and capsules. Activities include excipient selection refinement, granulation parameter optimization (wet, dry, fluid bed), compression profile establishment, oral solid dose coating process definition, disintegration and dissolution performance confirmation, and scale-up through pilot equipment trains. |
| Liquid and Reconstitutable Formulations | Development of solutions, suspensions, and powders for reconstitution. Work includes solubilization strategy optimization, suspension sedimentation and resuspendability testing, preservative efficacy evaluation, pH stability profiling, viscosity control, and fill-volume specification setting. |
| Injectable and Parenteral Formulations | Formulation optimization for solutions, emulsions, suspensions, and lyophilized products. Activities include tonicity and pH adjustment, surfactant and stabilizer optimization, terminal sterilization or aseptic processing compatibility assessment, sterile drug product container closure selection, and particulate matter control. |
| Semi-Solid and Topical Formulations | Refinement of creams, ointments, gels, and pastes. Key activities include rheological characterization, phase homogeneity assessment, API distribution verification, preservative system optimization, and compatibility testing with primary packaging (tubes, jars, pumps). |
| Modified-Release Formulations | Optimization of extended-release, delayed-release, and pulsatile-release systems. Work includes polymer matrix or membrane-controlled release profile tuning, coating level definition, in vitro release method development, and correlation of release profiles between development and pilot-scale batches. |
| Complex and Enabling Formulations | Development support for nanosuspensions, solid dispersions, lipid-based delivery systems, self-emulsifying formulations, and amorphous solid dispersions. Activities include solubility improvement strategy optimization, polymorphic form monitoring, micronization parameter control, and stability challenge testing under accelerated conditions. |
Share your lead formulation composition, target dosage form, manufacturing process details, analytical data, and development goals. Our specialists will design a project-specific plan covering formulation optimization, process R&D, scale-up studies, stability evaluation, packaging selection, and technology transfer documentation.
BOC Sciences reviews the existing formulation composition, process history, analytical data, stability results, and target product profile. We identify gaps between the current development state and late-stage readiness, including formulation robustness, process scalability, specification maturity, and data package completeness. A prioritized work plan is then aligned with the project timeline and manufacturing objectives.
Our team executes the optimization plan through iterative formulation adjustments, process parameter studies, and structured DoE campaigns. We characterize the relationship between formulation variables, process parameters, and critical quality attributes, then confirm that the optimized formulation and process perform consistently within the defined operating space.
The optimized formulation is scaled through intermediate to pilot batch sizes, with analytical monitoring at each stage to confirm product quality equivalence. Stability studies are initiated under appropriate storage conditions, and process performance data are collected to support validation documentation and technology transfer preparation.
Clients receive the optimized formulation composition, detailed manufacturing process description, analytical methods, specification justifications, stability data, and technology transfer documentation. We remain available for follow-up support during technology transfer, pilot plant implementation, and additional batch manufacturing as needed.
Early formulations may show acceptable initial quality but develop chemical degradation, physical instability, or performance changes during storage. BOC Sciences addresses this by systematically profiling degradation pathways through forced degradation and accelerated testing, then adjusting formulation composition — pH, buffer species and concentration, antioxidant levels, chelating agents, or excipient grades — to improve stability. We use HPLC, LC-MS, dissolution testing, and physical characterization at each stability time point to confirm that the refined formulation maintains target quality attributes under intended storage conditions.
Formulation and process conditions optimized at bench scale often produce different results in pilot equipment due to changes in shear forces, heat transfer, mixing dynamics, and material flow. BOC Sciences identifies scale-sensitive parameters through systematic process characterization, designs intermediate-scale confirmation batches to bridge bench and pilot conditions, and adjusts unit operation settings — impeller speed, granulation fluid addition rate, drying time, compression force — to maintain consistent particle size distribution, content uniformity, and dissolution performance.
Container closure systems can interact with drug products through leaching of packaging components, sorption of formulation ingredients, pH shifts, or moisture and oxygen permeation. BOC Sciences evaluates packaging compatibility through material screening, extraction studies, leachable profiling, and storage-oriented interaction studies. We assess multiple container options in parallel, testing formulation stability in each, and select the system that best protects product quality while meeting manufacturing and administration requirements.
Technology transfer can fail when process parameters defined on one equipment train do not translate directly to another due to differences in geometry, scale, automation, or operational practices. BOC Sciences prepares transfer packages that distinguish compound-dependent parameters from equipment-dependent settings, runs engineering batches at the receiving site with side-by-side analytical comparison, and provides on-site support during initial manufacturing. Our analytical method optimization and method development, validation, and transfer services ensure testing capability continuity across sites.
Partner with BOC Sciences to access comprehensive late-stage formulation development, process scale-up, stability assessment, packaging selection, and technology transfer services backed by integrated analytical capabilities and systematic data documentation.
We apply Design of Experiments (DoE) and multivariate analysis to understand how formulation and process variables interact and to define a robust operating space. This systematic approach reduces development cycles and produces a formulation supported by a clear data rationale rather than empirical iteration.
We design late-stage strategies around the specific properties of each molecule — solubility, stability, polymorphic tendency, and excipient compatibility. Our solubility analysis, polymorph screening, and excipient screening capabilities inform formulation decisions from the outset.
We adapt the scope to each program's current position. Some clients need targeted optimization to resolve a specific issue; others need full-scale process development and technology transfer documentation. This flexibility is supported by our formulation development platform and scale-up infrastructure.
We prepare structured packages covering formulation composition, manufacturing process descriptions, analytical methods, specification justifications, and stability data. These packages support internal decision-making, partner communication, and downstream manufacturing activities.
Client Needs: A pharmaceutical development team had an immediate-release tablet formulation of a BCS Class II compound that performed well at laboratory scale (1 kg) but showed reduced dissolution rate and content uniformity drift when processed at pilot scale (15 kg). The team needed formulation and process adjustments to restore product performance at the larger scale.
Challenges: The compound was hydrophobic with poor flow properties, and the initial wet granulation process produced granules with inconsistent density and particle size distribution at pilot scale. Tablet hardness and dissolution varied across compression runs, and sticking to tooling was observed during extended compression campaigns.
Solution: We conducted a DoE-based evaluation of granulation fluid addition rate, wet massing time, drying endpoint, and mill screen size across multiple pilot-scale batches. Dissolution testing, particle size analysis, and content uniformity assessment at each condition identified an operating window that restored consistent dissolution and content uniformity. A modified lubricant level and compression force range eliminated sticking while maintaining hardness and disintegration targets.
Outcome: The client received an optimized formulation and a documented pilot-scale manufacturing process with defined parameter ranges, supported by batch data demonstrating consistent dissolution, content uniformity, and tablet properties across three consecutive pilot batches.
Client Needs: A biotechnology company required late-stage formulation optimization for a lyophilized peptide injectable that exhibited visible particle formation and potency loss after six months of refrigerated storage. The existing formulation and container closure system needed evaluation and improvement.
Challenges: The peptide was sensitive to oxidation and prone to aggregation at low concentration. The initial lyophilization cycle produced cakes with variable moisture content, and extractable compounds from the rubber stopper appeared to contribute to particle formation over time.
Solution: We screened antioxidant type and concentration, buffer species and pH, bulking agent ratio, and surfactant level in a structured formulation study. The lyophilization cycle was re-optimized by adjusting freezing rate, primary drying temperature and pressure, and secondary drying duration. Three stopper types from different material families were evaluated through extractables profiling and stability comparison, leading to selection of a coated stopper that reduced particle formation.
Outcome: The client received an optimized lyophilized formulation with improved stability profile, a refined lyophilization cycle, a compatible container closure system, and a data package summarizing formulation rationale, process parameters, and comparative stability results.
To begin a project, clients may provide the active ingredient properties, current formulation composition, dosage-form requirements, available analytical data, known stability concerns, manufacturing process information, packaging preferences, and target storage conditions. Previous development reports and batch records can also help identify unresolved risks. BOC Sciences reviews the available information to determine data gaps, define the formulation and process variables requiring further study, and develop a project plan. The exact information and material quantities required depend on the dosage form, development stage, and intended project scope.
BOC Sciences supports late-stage development of oral solid formulations, liquid and reconstitutable products, injectable and parenteral formulations, semi-solid and topical products, modified-release systems, and complex or enabling formulations. Project design is adapted to the physicochemical properties of the active ingredient, administration route, formulation complexity, stability risks, and manufacturing requirements. Support may include composition refinement, excipient assessment, process optimization, analytical evaluation, scale-up studies, packaging compatibility assessment, and technical documentation. Feasibility and development priorities are evaluated individually because different dosage forms require distinct preparation processes and quality attributes.
Formulation optimization begins by identifying the variables most likely to influence product stability, manufacturability, and performance. These may include excipient type and level, pH, buffer composition, moisture content, mixing conditions, granulation parameters, drying conditions, or sterilization-compatible processing options. Structured experiments are then used to evaluate interactions among formulation and process variables. Selected formulations are compared using relevant physical, chemical, and performance-related attributes. The resulting data help define a practical operating range and select a formulation-process combination suitable for subsequent scale-up and batch reproducibility studies.
Stability support may include studies under selected long-term, accelerated, refrigerated, freeze–thaw, light-exposure, or in-use conditions, depending on the formulation and intended storage environment. BOC Sciences can monitor relevant attributes such as appearance, assay, degradation products, pH, moisture, particle size, viscosity, dissolution, reconstitution behavior, and particulate formation. The study design, sampling schedule, analytical methods, and acceptance criteria are established according to the project objectives and available product knowledge. Results are used to identify degradation pathways, compare formulation options, evaluate packaging interactions, and support evidence-based storage recommendations.
Yes. Packaging development may include screening container materials, closure systems, barrier properties, product-contact compatibility, adsorption risks, moisture or oxygen sensitivity, and container–closure performance. Once the formulation and process are sufficiently defined, BOC Sciences can organize formulation instructions, process parameters, analytical procedures, material requirements, risk observations, and supporting study results into a structured technical package. Technology transfer support may also include answering technical questions, comparing available equipment, assessing process differences between sites, and assisting with initial receiving-site activities to promote consistent implementation of the transferred formulation and manufacturing process.
BOC Sciences took our early tablet formulation and systematically scaled it from bench to pilot without sacrificing dissolution performance or content uniformity. Their DoE-driven approach identified the critical granulation and compression parameters quickly, and the pilot batches matched our target profile across all key attributes.
— Senior Formulation Scientist, Generic Pharmaceutical Company
We were under significant timeline pressure to generate stability data for our lead injectable formulation. BOC Sciences designed an efficient stability protocol, managed sample pull and testing on schedule, and delivered a well-organized stability report with clear degradation trend analysis that our team could immediately use.
— CMC Project Lead, Mid-Size Biotech
The technology transfer documentation BOC Sciences prepared was thorough and practical. Process parameters were clearly linked to quality attributes, analytical methods were well-described with qualification data, and the gap analysis between our sites saved us considerable troubleshooting time during the first engineering batch.
— Director of Pharmaceutical Development, Specialty Pharma
Our program required late-stage work on both an oral solid and a parenteral formulation simultaneously. BOC Sciences assigned dedicated teams to each, managed the parallel workflows efficiently, and maintained consistent quality standards and documentation formats across both projects. This flexibility was a major advantage for our small development group.
— Head of R&D, Emerging Biopharmaceutical Company
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
